Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Stung By Plunging Vitae Pharmaceuticals Inc (VTAE)

Page 1 of 2

Vitae Pharmaceuticals Inc (NASDAQ:VTAE) may have seemed to be a very good bet for hedge funds by the end of the first quarter, but the stock plunged over 40% from its closing price of $15.19 per share on Friday, June 26, to open today at $9 per share. The stock, though recovering some of those losses, is still currently down by over 17%. The sharp decline in the stock early today comes as the company revealed that its drug VTP-34072, that it is developing with Boehringer Ingelheim Pharmaceuticals, Inc. to help treat Type 2 diabetes in overweight patients, has failed to significantly reduce blood sugar levels of test subjects as an add-on therapy. The pharmaceutical companies hoped that VTP-34072 would be an add-on drug to a treatment regimen involving metformin, a common diabetes medication. VTP-34072 will undergo trial testing as a solitary drug in a treatment program later this year.

medications-pharmacy drugs

Based on the level of interest Vitae Pharmaceuticals Inc (NASDAQ:VTAE) got from hedge funds by the end of the first quarter, it appears that investors had high hopes for the company and perhaps this particular treatment. As the stock plunges today, investors who are still long on the stock will be taking big losses. Among hedge funds tracked by Insider Monkey, the company was in nine hedge funds’ portfolios at the end of said period, up from four at the end of the previous quarter. Total investments had grown as well, as the aggregate value of holdings increased to $36.31 million by the end of 2015’s maiden quarter, up 117.80% from the previous quarter. This is a very significant increase considering the stock declined a substantial 29.63% in the first quarter of this year. Funds clearly felt it was a great buy-low candidate during the quarter and loaded up.

At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically delivered a monthly alpha of six basis points, though these stocks underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month (read the details here). Since the official launch of our small-cap strategy in August 2012, it has performed just as predicted, returning over 145% and beating the market by more than 85 percentage points. We believe the data is clear: investors will be better off by focusing on small-cap stocks utilizing hedge fund expertise rather than large-cap stocks.

We also track insider moves in companies to see bets made by executives for or against their own firms. Vitae Pharmaceuticals Inc (NASDAQ:VTAE), according to our data, did not have any purchases of shares by insiders by the end of the first half of 2015. However, Director Donald Hayden Jr. sold 55,000 shares of the firm on Tuesday of last week.

With all of this in mind, we’re going to take a peek at the key hedge fund action surrounding Vitae Pharmaceuticals Inc (NASDAQ:VTAE).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!